Hep Fall 2014 – Special Issue
Hep Fall 2014 – Special Issue
In this issue, you’ll meet activist Lucinda Porter. Scroll down to click on her story and to see what else is inside.
Also Available On:
Features
Hep Hero
How one woman overcame hepatitis C and ended up helping others fight it, too.
From the Editor
Eye of the Tiger
The potential for up to millions of Americans to benefit from the new hep C meds makes this one of the most exciting moments in modern medicin...
Treatment News
Sovaldi-Ledipasvir Pill Safe With Major HIV Meds
Gilead Sciences’ fixed-dose combination pill of Sovaldi (sofosbuvir) and the investigational ledipasvir, likely to receive FDA approval on Oct...
’3D’ Cures 99% to 100% of Genotype 1b
AbbVie’s so-called ’3D’ combo regimen ditched ribavirin and still cured 99 percent to 100 percent of study participants with genotype 1b of he...
Daclatasvir and Asunaprevir Cure Up to 87% of 1b
Bristol-Myers Squibb’s daclatasvir and asunaprevir cured 81 percent to 87 percent of people with genotype 1b of hepatitis C in a recent Phase...
Primary Care Docs Clueless About Hep C Drugs
About three out of four primary care physicians (PCPs) are unfamiliar with the new generation of hep C drugs which received U.S. Food and Drug...
Hep C Suppression Linked to Major Health Benefits
Suppressing the hep C viral load is associated with a diminished risk of liver disease and death.
Curing Hep C Lowers Central Nervous System Fatigue
Ridding the body of hep C reduces central fatigue, which is weakness originating in the central nervous system.
